Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$40.90 USD
-0.32 (-0.78%)
Updated May 10, 2024 04:00 PM ET
After-Market: $40.88 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RARE 40.90 -0.32(-0.78%)
Will RARE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RARE
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Repligen (RGEN) Misses Q1 Earnings Estimates
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Other News for RARE
RARE December 2025 Options Begin Trading
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Illumina (ILMN)
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Ultragenyx price target lowered by $2 at Canaccord, here's why